Email this article Influence of alpha1-adrenoblockers on the ejaculatory function of patients with benign prostatic hyperplasia
- Authors: Dianov M.P.1, Kyzlasov P.S.2, Martov A.G.2
-
Affiliations:
- S.V. Belyaev Kuzbass Regional Clinical Hospital
- State Research Center — Burnasyan Federal Medical Biophysical Cente
- Issue: Vol 14, No 1 (2024)
- Pages: 45-50
- Section: Original articles
- URL: https://journal-vniispk.ru/uroved/article/view/257397
- DOI: https://doi.org/10.17816/uroved606681
- ID: 257397
Cite item
Open Access
Access granted
Subscription Access
Abstract
BACKGROUND: The cause of ejaculatory dysfunction in patients with benign prostatic hyperplasia can be either the disease itself or its surgical or drug treatment, including the use of alpha1-blockers.
AIM: To study the effect of alpha1-blockers on the ejaculatory function of patients with benign prostatic hyperplasia.
MATERIALS AND METHODS: Under observation were 90 patients with benign prostatic hyperplasia aged from 56 to 79 years, who were distributed into 3 groups of 30 people. Patients of the group 1 were prescribed tamsulosin at a dose of 0.4 mg once a day, patients of the group 2 were prescribed silodosin at a dose of 8 mg once a day, and patients of the group 3 were prescribed alfuzosin 10 mg once a day. Duration of treatment is 4 weeks. To assess the effectiveness of treatment and its impact on copulatory function before and after treatment, patients filled out the IPSS, IIEF-5, ICF and MSHQ questionnaires.
RESULTS: The reduction in the severity of clinical manifestations of benign prostatic hyperplasia and the improvement in quality of life in patients of the three groups were the same. The effect of alpha1-blockers on erectile function has not been noted. A significant decrease in ejaculatory function was revealed in patients of the groups 1 and 2, while in patients of the group 3 no changes in ejaculatory function were observed.
CONCLUSIONS: When planning drug therapy for patients with benign prostatic hyperplasia, it is necessary to take into account the specific effects of different alpha1-blockers on ejaculatory function.
Full Text
##article.viewOnOriginalSite##About the authors
Maksim P. Dianov
S.V. Belyaev Kuzbass Regional Clinical Hospital
Email: dianovmp@gmail.com
ORCID iD: 0009-0008-7183-1369
Urologist, Urological Division
Russian Federation, 22 Oktyabrskii av., Kemerovo, 650000Pavel S. Kyzlasov
State Research Center — Burnasyan Federal Medical Biophysical Cente
Email: Dr.kyzlasov@mail.ru
ORCID iD: 0000-0003-1050-6198
SPIN-code: 6806-7913
Scopus Author ID: 57196124148
MD, Dr. Sci. (Medicine)
Russian Federation, MoscowAleksey G. Martov
State Research Center — Burnasyan Federal Medical Biophysical Cente
Author for correspondence.
Email: martovalex@mail.ru
ORCID iD: 0000-0001-6324-6110
SPIN-code: 5680-0899
corresponding member of RAS, Dr. Sci. (Medicine), Professor
Russian Federation, MoscowReferences
- Apolihin OI, Komarova VA, Nikushina AA, Sivkov AV. Prostate diseases in the Russian Federation: statistical data for 2008–2017. Experimental and clinical urology. 2019;(2):4–13. EDN: DHXMJP doi: 10.29188/2222-8543-2019-11-2-4-12
- LLC “Russian Society of Urologists”. Clinical Recommendations of the Ministry of Health of the Russian Federation “Benign prostatic hyperplasia”, 2020. Available from: https://cr.minzdrav.gov.ru/schema/6_1?ysclid=lukv36kwbm720871222 (In Russ.)
- Lukianov IV, Kotov SV. Drug therapy for benign prostatic hyperplasia and sexual dysfunction. The clinician. 2006;1(3):40–46. EDN: LPBAWF
- Glybochko PV, Alyaev YG, Chaly ME, et al. Sexual disorders in men. Moscow: GEOTAR-Media, 2012. 112 p. (In Russ.)
- Korshunov MN, Korshunova ES, Darenkov SP. Retarded ejaculation. Etiology, diagnosis, therapy. Reproductive aspects of the problem. Kremlin Medicine Journal. 2017;(2):79–85. EDN: YPIFJN
- Tyuzikov IA. Ejaculatory dysfunctions in men as a modern interdisciplinary medical and social problem. Medical alphabet. 2014;3(16):19–24. EDN: STHDTD
- Kholodniy VA. Symptomatic sexual dysfunctions in urological practice. Experimental and clinical urology. 2013;(4):58–65. EDN: RVFGFZ
- Al-Shukri SKh, Zhuravlev VN, Kogan MI, et al. A study of sexual function of patients with benign prostatic hyperplasia during treatment with alfuzosin. RMJ. 2008;16(29):1997–2001. EDN: TIMAOB
- Capogrosso P, Serino A, Ventimiglia E, et al. Effects of silodosin on sexual function — realistic picture from the everyday clinical practice. Andrology. 2015;3(6):1076–1081. doi: 10.1111/andr.1209
- Pushkar DYu, Rasner PI. Lower urinary tract symptoms and benign prostatic hyperplasia. Urologiia. 2018;(S1):30–45. EDN: YLVSNN
- Tang D-D, Li C, Peng D-W, Zhang X-S. Validity of premature ejaculation diagnostic tool and its association with International Index of Erectile Function-15 in Chinese men with evidence-based-defined premature ejaculation. Asian J Androl. 2018;20(1):19–23. doi: 10.4103/aja.aja_9_17
- Rosen RC, Catania JA, Althof SE, et al. Development and validation of four-item version of Male Sexual Health Questionnaire to assess ejaculatory dysfunction. Urology. 2007;69(5):805–809. doi: 10.1016/j.urology.2007.02.036
- Zhang X, Tang D, Xu C, et al. The relationship between self-estimated intravaginal ejaculatory latency time and International Prostate Symptom Score in middle-aged men complaining of ejaculating prematurely in China. J Sex Med. 2015;12(3):705–712. doi: 10.1111/jsm.12811
- Martov AG, Dukhanin AS, Bernikov AN. Current issues in alpha1-adrenergic blocker therapy: integration of pharmacological approach and clinical experience. Urologiia. 2022;(3):166–175. EDN: IJAQZM doi: 10.18565/urology.2022.3.166-175
Supplementary files
